Sunburst Financial Group LLC Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Sunburst Financial Group LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDXFree Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 965 shares of the medical instruments supplier’s stock, valued at approximately $235,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Householder Group Estate & Retirement Specialist LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $25,000. OFI Invest Asset Management bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Indiana Trust & Investment Management CO bought a new position in Becton, Dickinson and Company during the third quarter worth $27,000. OLD Point Trust & Financial Services N A acquired a new stake in Becton, Dickinson and Company in the second quarter worth $36,000. Finally, CGC Financial Services LLC acquired a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $37,000. Institutional investors and hedge funds own 86.72% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on BDX shares. Morgan Stanley decreased their target price on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating for the company in a research report on Monday, December 4th. Raymond James increased their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $279.17.

Check Out Our Latest Stock Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded down $0.46 during trading on Friday, hitting $236.71. The company’s stock had a trading volume of 2,683,003 shares, compared to its average volume of 1,515,916. The business has a fifty day moving average of $238.54 and a 200-day moving average of $247.09. The company has a market cap of $68.39 billion, a PE ratio of 56.09, a P/E/G ratio of 1.97 and a beta of 0.42. Becton, Dickinson and Company has a 52 week low of $229.85 and a 52 week high of $287.32. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.98 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. The ex-dividend date of this dividend is Thursday, March 7th. Becton, Dickinson and Company’s dividend payout ratio is currently 90.05%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.31% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.